Cartesian Therapeutics Inc. (1S70)
XMUN 
Summary
1S70 Chart
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?
Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cartesian Therapeutics Inc. (1S70) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cartesian Therapeutics Inc. ever had a stock split?
Cartesian Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Carsten Brunn CEO | XMUN Exchange | US8162123025 ISIN |
| US Country | 75 Employees | - Last Dividend | 5 Apr 2024 Last Split | - IPO Date |
Overview
Cartesian Therapeutics, Inc. is a trailblazing clinical-stage biotechnology firm dedicated to advancing the field of medicine through its innovative approach in mRNA cell therapies. With a focus on treating various autoimmune diseases, the company stands at the forefront of developing therapies that aim to revolutionize the way such conditions are treated. Cartesian Therapeutics is founded on a commitment to leveraging advanced science to create impactful solutions for patients struggling with autoimmune disorders. Headquartered in Gaithersburg, Maryland, the company embodies a spirit of innovation and a relentless pursuit of excellence in biotechnology.
Products and Services
Cartesian Therapeutics, Inc. has developed a robust pipeline of groundbreaking mRNA cell therapies designed to address a wide range of autoimmune diseases through innovative treatment modalities. Here's an overview of their leading products under development:
- Descartes-08: This cutting-edge product is an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell (CAR-T) therapy, which is currently in Phase 2b clinical development. It's specifically designed for treating generalized myasthenia gravis and is also being evaluated for its potential in treating patients with systemic lupus erythematosus. Furthermore, Descartes-08 is involved in myeloma autoimmune basket trials, exploring its utility in other autoimmune diseases.
- Descartes-15: Aimed at addressing both autoimmune diseases and myeloma, Descartes-15 represents another significant stride in Cartesian Therapeutics' pursuit of novel treatments. While specific details regarding its mechanism of action and development stage remain concise, Descartes-15 underscores the company's commitment to broadening its impact across multiple autoimmune conditions.
- Descartes-33: This product is currently in preclinical development and showcases Cartesian Therapeutics' ongoing efforts to extend its research and development into new therapeutic areas. Descartes-33 is focused on treating autoimmune diseases, indicating the company's continuous endeavor to innovate and expand its portfolio of solutions for autoimmune disorders.
